Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics

Monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal target recognition module of a conventional antibody is composed of two non-covalently associated variable domains (VH an...

Descripción completa

Detalles Bibliográficos
Autores principales: Bannas, Peter, Hambach, Julia, Koch-Nolte, Friedrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702627/
https://www.ncbi.nlm.nih.gov/pubmed/29213270
http://dx.doi.org/10.3389/fimmu.2017.01603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702627/
https://www.ncbi.nlm.nih.gov/pubmed/29213270
http://dx.doi.org/10.3389/fimmu.2017.01603

Ejemplares similares